CE Mark Granted for Rapid Bacterial vs Viral Infection Test
The high-throughput host-response assay provides results in approximately 20 minutes to help guide treatment decisions and antimicrobial stewardship.
The high-throughput host-response assay provides results in approximately 20 minutes to help guide treatment decisions and antimicrobial stewardship.
The collaboration will provide quality assessment products to support the commercialization of a molecular point-of-care assay for COVID-19 and influenza detection.
Roche introduced the cobas Respiratory flex test which uses TAGS technology to identify up to 15 pathogens in a single PCR test.
QIAGEN’s QIAstat-Dx Respiratory Panel Plus, a syndromic testing tool for diagnosing respiratory infections, received FDA clearance.
Read MoreADLM’s new guidance on clinical testing for respiratory viral infections emphasizes the use of advanced diagnostic methods and sample types.
Read MoreResearchers demonstrated that metal-enhanced fluorescence probes could rapidly detect influenza virus proteins without complex lab equipment.
Read MoreEvidation has been awarded a contract by BARDA to fund the 2023 Influenza-like Illness (ILI) Detect & Protect Studies.
Read MoreA parallel test developed by Karius aims to improve treatment for serious diseases by diagnosing infections more rapidly and effectively.
Read MoreThe new biochip offers the potential to test multiple pathogens responsible for respiratory infections, such as COVID, RSV, and influenza.
Read MoreNew data provides a unique snapshot of the interplay among SARS-CoV-2, influenza, and respiratory syncytial virus (RSV).
Read MoreSAS and the Texas DSHS are teaming up on new public health dashboards powered by SAS Viya for tracking influenza data across the state.
Read MoreSekisui Diagnostics’ OSOM Ultra Plus Flu A&B Test is a rapid antigen test that takes only 10 minutes at the point of care.
Read MoreHologic Inc. announced that the FDA has granted 510(k) clearance for the company’s Panther Fusion SARS-CoV-2/Flu A/B/RSV assay.
Read MoreCue Health announced that it has made a De Novo submission to the FDA for full clearance of the Cue RSV Molecular Test.
Read MoreScientists report using a nanomaterials-based sensor that can detect the presence of the viruses that cause COVID-19 and the flu.
Read MoreBD received Emergency Use Authorization from the US FDA for a new molecular diagnostic combination test for respiratory viruses.
Read MoreNomi Health is expanding its testing offerings to include influenzas A and B at its Utah COVID-19 testing sites.
Read MoreA new method of rapid, yet quantitative and specific point-of-care detection of antibodies uses an electrochemical cell-free biosensor.
Read More